TFF Pharmaceuticals 株価情報 (NASDAQ: TFFP)

最新ニュース TFF Pharmaceuticals (NASDAQ:TFFP) 株価情報

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

TFF Pharmaceuticals Inc

California cannabis company Lowell Farms Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LOWLF#OTCQX">LOWLF</a>) announced its unaudited revenue and operating results Thursday for the third quarter of 2024, reporting net revenue of $3.2 million, down 48% from $6.2 million in the same period last year. Net revenue decreased by 8% from $3.5 million in the second quarter of 2024.
"We're happy to share the progress Lowell Farms made towards expanding our footprint into the California retail market," stated co-founder and CEO Mark Ainsworth. "This strategic move marks a new chapter for us, enabling us to further showcase the strength of our brand portfolio, now in our own retail spaces and deliver an enhanced customer experience. As we focus on strategic, selective growth, we're confident that this expansion will solidify Lowell's position in the market, bringing us closer to our vision for sustainable and meaningful growth."
Read Also: <a href="https://www.benzinga.com/24/11/41982261/im-cannabis-achieves-66-revenue-growth-in-germany-narrows-ebitda-loss-in-q3">IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 Financial Highlights</h2>
<ul>
<li>CPG revenue decreased 26% compared to the same quarter of 2023.</li>
<li>Bulk product revenue from self-grown wholesale products was $nil million compared to $1.2 million for the quarter ended Sept. 30, 2023, reflecting our exit from the cultivation facility in January 2024.</li>
<li>Gross margin was negative 29.0% representing a gross loss of $900,000, reflecting the sell through of higher cost inventory associated with the cultivation facility which adversely impacted cost of goods sold by $600,000 in the third quarter.</li>
<li>Operating loss was $2.8 million, compared to operating loss of $2.9 million for the same period last year.</li>
<li>Net loss was $3.6 million compared to a net loss of $20.2 million for the comparable period of 2023.</li>
<li>Adjusted EBITDA was negative $2.1 million compared to adjusted EBITDA of negative $1.4 million for the third quarter last year.</li>
</ul>
<h2 class="wp-block-heading">Price Action</h2>
Lowell Farms shares closed Thursday's market session flat at $0.015 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a> 

</li>
</ul>
Photo: Courtesy of YARphotographer via Shutterstock

Cannabis

Earnings

News

LOWLF

California Cannabis Company Lowell Farms Reports 48% YoY Revenue Decline In Q3

<a href="https://www.globenewswire.com/Tracker?data=TasyziQV3sWM0A4NpDTDXXuoGzlj19faWYDgmgak5zdeB0NwGr7ExJHPjJx-Yk3xdZyZlmGcFLHgW-Xo4jWMwJ5-GZr_WKDNiItVThueFOE=">Red Cat Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) ("Red Cat"), a drone technology company building hardware and software for military, government, and commercial operations, today announced that it will hold a Town Hall Meeting for investors, analysts and members of the media on Tuesday, November 19, 2024.
Company management will provide an update on new developments for Black Widow&#x2122;, which the company introduced as part of its ARACHNID&#x2122; Family of Small ISR and Precision Strike Systems at AUSA 2024. Following management's formal remarks, there will be a question-and-answer session.

Events

RCAT

Red Cat Announces It Will Hold A Town Hall Meeting For Investors, Analysts And Members Of The Media On Tuesday, November 19, 2024; Will Provide An Update On New Developments For Black Widow

WIIM

MAMO

Massimo Group shares are trading lower after the company reported a year-over-year decrease in Q3 financial results.

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending Nov. 15:
Axon Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>): The weapons and cloud-based digital evidence company was one of many that<a href="https://www.benzinga.com/news/large-cap/24/11/41886058/donald-trump-victory-week-nov-4-8-these-large-cap-stocks-were-biggest-gainers"> saw strong interest </a>from investors after the 2024 presidential election was won by Donald Trump. 
The company recently reported third-quarter revenue of $544.3 million, up 32% year-over-year. The revenue total beat a Street consensus estimate of $525.1 million. Axon also reported earnings per share of $1.45, which beat a Street estimate of $1.20. 
The quarter continued a streak of consecutive quarters of beating analyst estimates, which now stands at 10 for both revenue and earnings per share. Axon also shared revenue guidance for the fourth quarter with an expected range of $560 million to $570 million, ahead of a Street estimate of $523 million. 
Analysts <a href="https://www.benzinga.com/quote/AXON/analyst-ratings">raised price targets</a> on Axon after the earnings and 2024 election. Northland maintained an Outperform rating and raised the price target from $365 to $550, Needham maintained a Buy rating and raised the price target from $525 to $600 and Baird maintained an Outperform rating and raised the price target from $460 to $600.
Axon shares were up over 11% over the last five days, as of writing. The stock is up over 140% year-to-date in 2024. The Axon <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> is below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241.png" alt="" class="wp-image-650644" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111044/Screenshot-241-768x375.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>): The cloud and data company is seeing increased interest ahead of third-quarter financial results. The company will report third-quarter results after market close on Nov. 20. Analysts expect the company to report earnings per share of 15 cents, down from 25 cents and revenue of $897.6 million, up from $734.2 million. 
The company has beaten analyst estimates for earnings per share in nine of the past 10 quarters and for revenue in more than 10 straight quarters. 
Snowflake's second-quarter revenue was up 29% year-over-year with product revenue up 30% year-over-year and the company's net revenue retention rate at 127% in the quarter. Snowflake reported remaining performance obligations of $5.2 billion and a total of 510 customers.
"With the combination of our platform, the network effect of collaboration and our AI innovations, we have a huge opportunity ahead to deliver even greater value to deliver even greater value to our customers," Snowflake CEO Sridhar Ramaswamy said after<a href="https://www.benzinga.com/news/earnings/24/08/40494892/snowflake-q2-earnings-revenue-beat-eps-beat-raised-guidance-additional-2-5b-buyback-great-traction-"> second-quarter results.</a>
With cybersecurity a key theme moving forward <a href="https://www.benzinga.com/24/11/41849944/financial-crime-weekly-alleged-snowflake-hacker-arrested-banned-china-chip-shipments-payday-advance-company-sued">and recent hacks,</a> Snowflake stock could continue to see interest from investors. Snowflake stock was up around 5% over the last week, but shares are down more than 30% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242.png" alt="" class="wp-image-650645" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111102/Screenshot-242-768x386.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>): The electrical and manufacturing construction and facilities services provider is <a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">back on the Stock Whisper Index</a>. 
The company recently reported third-quarter financial results with earnings per share beating analyst estimates and revenue missing estimates. Guidance from the company was similar with full-year revenue guidance of revenue set at $14.5 billion, down from a prior range of $14.5 billion to $15.0 billion and below a Street estimate of $14.7 billion. 
EMCOR expects full-year earnings per share of $20.50 to $21, up from a previous range of $19 to $20 and ahead of a Street estimate of $19.53 per share. The stock could benefit from interest rate cuts and the administration. 
Stifel <a href="https://www.benzinga.com/quote/EME/analyst-ratings">recently initiated </a>the stock with a Buy rating and $600 price target. The stock was up after the 2024 election before cooling off in the past week. Shares were down on the week, but remain up over 130% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243.png" alt="" class="wp-image-650647" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111119/Screenshot-243-768x375.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): The space and rocket company continues to see strong interest from readers. The company reported<a href="https://www.benzinga.com/general/space/24/11/41922070/rocket-lab-q3-earnings-revenue-beat-eps-beat-continued-strong-demand-growth-multi-launch-agreement-air-force-award-and-more"> third-quarter financial results</a> recently with revenue of $104.8 million and earnings per share of a loss of 10 cents per share both beating analyst estimates. 
Rocket Lab's revenue was up 55% year-over-year in the quarter. The company has already passed a new annual launch record with 12 Electron launches so far, with more scheduled in November and December. Rocket Lab highlighted its backlog of over $1 billion and strong demand growth in the quarterly results.
"We expect to close out the year strongly with more Electron launches scheduled in November and December, alongside continued progress across Neutron and space systems, that is behind our guidance for a record $125-$135 million revenue quarter in Q4," Rocket Lab CEO Peter Beck said.
The company also announced a multi-launch agreement with an unnamed commercial satellite company and an award from the U.S. Air Force Research Laboratory worth up to $8 million.
Beck highlighted the company's backlog including over 40 spacecraft that range from missions to Mars, national security and telecommunications projects for partners during an <a href="https://www.benzinga.com/general/space/24/11/41961309/rocket-lab-ceo-touts-spacex-rival-status-trump-impact-on-space-as-stock-surges-almost-30">interview on CNBC. </a>Beck also expressed optimism about space policy under incoming President Donald Trump.
Analysts <a href="https://www.benzinga.com/quote/RKLB/analyst-ratings">raised their price targets</a> on Rocket Lab after the quarterly financial results. The stock was up 30% over the past five days and is up over 225% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="485" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244.png" alt="" class="wp-image-650648" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111135/Screenshot-244-768x372.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
The Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>): The advertising company saw strong interest from readers after reporting<a href="https://www.benzinga.com/news/earnings/24/11/41830188/the-trade-desk-stock-is-tumbling-after-the-bell-whats-going-on"> third-quarter financial results.</a> Third-quarter earnings per share of 41 cents beat a street estimate of 39 cents per share and revenue of $628.0 million beat a Street estimate of $620 million. 
The company has now beaten analyst estimates for earnings per share in nine of the past 10 quarters and beaten revenue estimates in more than 10 straight quarters. Trade Desk said its customer retention was over 95% in the quarter.
"As we enter our busiest time of year and look ahead to 2025, we have never been in a better position to capture a greater share of the $1 trillion advertising TAM," The Trade Desk CEO Jeff Green said.
Trade Desk's guidance for the fourth quarter came in ahead of Street estimates for revenue. Several analysts <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">raised their price targets </a>on the stock after the quarterly results.
Trade Desk shares were down 5.11% over the past five days and the stock is up 78% year-to-date in 2024, as of writing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245.png" alt="" class="wp-image-650649" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15111150/Screenshot-245-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">November 1</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">November 8</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes" target="_blank" rel="noreferrer noopener">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>

SPACE

Exclusives

Trading Ideas

AXON

RKLB

SNOW

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

ATXI

Avenue Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results

Offerings

On Thursday November 14, 2024, Red Cat Holdings Filed For $100M Mixed Securities Shelf

Starbucks's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>) short percent of float has fallen 11.2% since its last report. The company recently reported that it has 25.17 million shares sold short, which is 2.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Starbucks Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689169_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Starbucks has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Starbucks's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Starbucks's peer group average for short interest as a percentage of float is 10.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SBUX

(SBUX) - Analyzing Starbucks's Short Interest

Selective Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NYSE">SIGI</a>) short percent of float has risen 4.28% since its last report. The company recently reported that it has 1.24 million shares sold short, which is 2.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Selective Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689164_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Selective Insurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Selective Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Selective Insurance Gr's peer group average for short interest as a percentage of float is 1.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SIGI

Peering Into Selective Insurance Gr's Recent Short Interest

Inhibikase Therapeutics shares are trading lower. The stock may be moving on continued weakness after reporting worse-than-expected Q3 EPS results yesterday.

Element Solutions's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) short percent of float has risen 4.05% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Element Solutions Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731689158_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Element Solutions has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Element Solutions's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Element Solutions's peer group average for short interest as a percentage of float is 3.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Element Solutions?

Student loan policies could be overhauled under President-elect Donald Trump&#8217;s upcoming administration, with several existing programs likely to undergo changes or be eliminated.
The Biden administration&#8217;s Saving on a Valuable Education (SAVE) repayment plan, currently serving eight million borrowers, stands at a crossroads. The program&#8217;s fate hangs in the balance as the 8th Circuit Court of Appeals weighs its legality, with no clear indication that Trump&#8217;s administration would continue defending it.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
&#8220;The reason [the Biden] administration is defending the rule so vigorously is it was providing a much more affordable repayment plan,&#8221; Persis Yu, deputy executive director at Student Borrower Protection Center, told CNBC Make It last week.
Trump&#8217;s previous term offers insights into potential policy directions. According to CNBC, his administration proposed eliminating Public Service Loan Forgiveness and slashed funding for various higher education programs. During that period, roughly 99% of PSLF applicants faced rejection by 2019, leading to legal action from teachers&#8217; unions against then-Secretary of Education Betsy DeVos.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
The administration&#8217;s approach to borrower protections also shifted. Rules were loosened for institutions to demonstrate student success outcomes, resulting in an estimated $11 billion reduction in debt relief for borrowers affected by questionable academic programs, particularly at for-profit colleges.
Project 2025, a policy agenda developed by The Heritage Foundation, outlines more dramatic changes. While <a href="https://www.benzinga.com/news/24/07/39874558/trump-disassociates-himself-from-extreme-project-2025-at-michigan-rally-i-dont-know-what-the-hell-it">Trump has distanced himself from the proposals</a>, the agenda calls for eliminating PSLF and borrower defense programs. More importantly, it proposes dismantling the Department of Education and returning to private lender dominance in education financing.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
The shift toward private lending raises concerns among borrower advocates. &#8220;What kind of corporate interests are going to be protected over the interests of borrowers and students,&#8221; Yu said to CNBC. Private student loans typically carry higher costs as lenders set interest rates independently, unlike federal loans, where Congress determines rates.
The transition could leave millions of borrowers in limbo regarding their monthly payments. Biden&#8217;s alternative debt relief plan, targeting long-term borrowers and those from low-value academic programs, faces legal challenges that the Trump administration appears unlikely to defend against Republican-led lawsuits.
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
The landscape marks a pivot from March 2020, when <a href="https://www.benzinga.com/government/24/09/40780284/student-loan-protection-soon-ends-9-7m-borrowers-should-be-worried-about-their-credit-ratings">Trump initiated the pandemic-related payment pause</a>. That policy lasted throughout his term and provided widespread relief to federal loan borrowers. His return to office signals a potentially different approach to student debt management, emphasizing private sector solutions over federal programs.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Is Trump's Second Term Going To Affect Student Loan Borrowers? Here Are 3 Potential Changes

CELC

Celcuity shares are trading lower after the company reported worse-than-expected Q3 EPS results.

<a href="https://www.wsj.com/politics/larry-kudlow-economic-role-trump-cabinet-3af2a446?mod=latest_headlines">https://www.wsj.com/politics/larry-kudlow-economic-role-trump-cabinet-3af2a446?mod=latest_headlines</a>
<a href="https://www.wsj.com/topics/person/donald-trump">Donald Trump</a> is considering tapping Fox Business Network host Larry Kudlow for a senior economic policy role in his administration, according to people familiar with the matter, amid the president-elect's mounting frustration with <a href="https://www.wsj.com/politics/policy/trump-transition-co-chair-makes-late-play-for-treasury-secretary-f1b50c60?mod=article_inline">jockeying for top jobs</a>.
Kudlow met with Trump at Mar-a-Lago, the president-elect's private Florida club, late this week, the people said. Trump's advisers see Kudlow as a contender to lead the National Economic Council and possibly the Treasury Department.&nbsp;

Macro Economic Events

Politics

Economics

General

'Trump Considers Fox Business Host Larry Kudlow For Top Economic Jobs; Former National Economic Council Director Met With Trump At Mar-A-Lago This Week' - WSJ

ORGN

Origin Materials shares are trading lower after the company reported worse-than-expected Q3 financial results.

DESP

Despegar shares are trading higher after the company reported better-than-expected Q3 financial results.

DPRO

Draganfly shares are trading lower after the company reported worse-than-expected Q3 revenue results. HC Wainwright & Co. cut its price target on the stock from $7 to $5.

Microsoft Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) latest advertising campaign, "This Is An Xbox," has quickly become a talking point, drawing mixed <a href="https://www.benzinga.com/general/gaming">reactions from fans. </a>
The campaign doubles down on the idea that Xbox isn't confined to a single console but exists as a gaming platform accessible on phones, TVs and PCs.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41948549/xbox-handheld-a-few-years-out-says-microsoft-gaming-ceo-hints-at-cross-platform-games-new-acquisitions">Xbox Handheld &#8216;A Few Years Out,&#8217; Says Microsoft Gaming CEO; Hints At Cross-Platform Games, New Acquisitions</a>
The ads lean into this concept with quirky imagery, showing things like a TV, a cellphone, a bento box and even a cat box labeled as "Xbox."
<h1 class="wp-block-heading">Fans Push Back on Microsoft's Strategy</h1>
The campaign has become a meme almost overnight, with critics voicing concerns over the decline of the Xbox console's significance. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is an Xbox. <a href="https://t.co/7l8DhCI8EX">pic.twitter.com/7l8DhCI8EX</a>
&mdash; Jez (@JezCorden) <a href="https://twitter.com/JezCorden/status/1857277902485590260?ref_src=twsrc%5Etfw">November 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">THIS IS AN XBOX &#x1f923; <a href="https://t.co/u6Jg986O7f">https://t.co/u6Jg986O7f</a> <a href="https://t.co/qroMlziI9e">pic.twitter.com/qroMlziI9e</a>
&mdash; &#x2699;&#xFE0F;The Gaming GrindHouse&#x2699;&#xFE0F; (@jez7780) <a href="https://twitter.com/jez7780/status/1857082844511658058?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Over the past few years, Microsoft has focused less on selling hardware and more on <a href="https://www.benzinga.com/general/gaming/24/10/41318405/microsoft-to-test-cloud-gaming-for-owned-xbox-games-in-november-report">expanding its gaming ecosystem.</a>
For core Xbox fans, this shift has been disappointing. Console exclusives are increasingly rare, and the <a href="https://www.benzinga.com/general/gaming/24/07/40081075/microsoft-reports-sharp-decline-in-xbox-hardware-sales-for-q4-but-theres-a-silver-lining">Xbox Series X and S have struggled to keep pace</a> with competitors in sales. The "box" that once defined the brand feels less central than ever.
<h1 class="wp-block-heading">Phil Spencer Xbox&#8217;s New Direction</h1>
Xbox CEO Phil Spencer addressed these concerns in a recent interview <a href="https://www.rollingstone.com/culture/rs-gaming/xbox-console-future-cloud-ceo-phil-spencer-1235166597/">with </a>Rolling Stone. "It literally was a box when it first launched. It was the Direct X box. What it's grown into now is more accessibility. Xbox isn't just one device, Xbox is on your smart TV, Xbox is on your PC, Xbox is on your phone, and we're in the middle of that transition."
"Some people long for the simplicity of a single box, single platform, single game," he said. But he argued that today's gaming landscape has changed, referring to platforms like <a href="https://www.benzinga.com/topic/fortnite">Fortnite</a> and <a href="https://www.benzinga.com/general/gaming/24/10/41255828/roblox-denies-hindenburgs-accusations-of-inflating-metrics-failing-at-child-safety-calls-them-misl">Roblox.</a> "Today's largest games are bigger than any of the individual platforms."
&#8220;I think the thing that should really have longevity are the games, characters, and world — and the platforms should enable us to experience those games where we want to play," he added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41750999/xbox-game-pass-november-metal-slug-tactics-flight-simulator-lead-new-releases">Xbox Game Pass November: Metal Slug Tactics, Flight Simulator Lead New Releases</a></li>
</ul>
Photo: Microsoft.

Gaming

MSFT

Phil Spencer Responds To 'This Is An Xbox' Criticism: 'We're In The Middle Of A Transition'

GAME

GameSquare shares are trading lower after the company reported worse-than-expected Q3 revenue results.

REKR

Rekor Systems shares are trading lower after the company reported worse-than-expected Q3 financial results.

Fundamental Global shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the first quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$2.40. This was below the analyst estimate for EPS of -$2.26.</li><li>The company reported revenue of $203,273.</li><li>This was 190.39% better than the analyst estimate for revenue of $70,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tffp-stock-earnings-tff-pharmaceuticals-for-q1-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;



Bottom-picking is risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to mitigate those risks.&nbsp;



For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;



This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. 



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a>The growing demand for EVs has spotlighted companies like Microvast Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;



The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;



Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;



In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;



TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.



A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.



Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.



But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div>Formerly known as Knowledgetree Ventures, My Size (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/">MYSZ</a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;



While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;



My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;



Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;



On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the second quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

TFF Pharmaceuticals to wind down operations

TFF Pharmaceuticals ( ($TFFP) ) has provided an announcement. TFF Pharmaceuticals, Inc. is set to dissolve following its board's approval of a liqu...

TFF Pharmaceuticals to Dissolve and Liquidate Assets

16:45 EST TFF Pharmaceuticals (TFFP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

TFF Pharmaceuticals trading resumes

MVST

MYSZ

TFFP

Health Care

Press Releases

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

TFF Pharmaceuticals Announces It Will Wind Down Operations

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Artelo Biosciences

Aytu BioPharma

Biofrontera

Cingulate

CNS Pharma

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NRX Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

ProPhase Labs

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

Roth MKM

HC Wainwright & Co.

JonesTrading

B. Riley Securities

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

Comments

TFF Pharmaceuticals

ニュース

最新ニュース TFF Pharmaceuticals (NASDAQ:TFFP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル